Faruqi & Faruqi, LLP reminds investors of the August 4, 2026 deadline to seek lead plaintiff in a securities class action against Grail, Inc. The lawsuit alleges that Grail and its executives made false and misleading statements about the likelihood of success of its NHS-Galleri cancer detection trial, touting confidence in its effectiveness while concealing that the trial period was likely insufficient to achieve the primary endpoint of a statistically significant reduction in Stage III and IV cancers. On February 19, 2026, Grail announced the primary endpoint was not observed, causing its stock price to fall from $101.53 to $50.21 per share, a decline of about 50.55% in a single day. Investors who purchased or acquired Grail securities between May 13, 2025 and February 19, 2026 may be eligible to participate.
GRAIL, LLCSecurities class action lawsuit alleging false statements about trial results, causing 50% stock drop.